芪胶升白胶囊对改善非小细胞肺癌患者化疗所致中性粒细胞减少症的临床药物疗效研究与分析

Study and analysis on clinical drug efficacy of Qijiaoshengbai capsule on the treatment of non-small cell lung cancer patients with neutropenia caused by chemotherapy

目的探讨芪胶升白胶囊对改善非小细胞肺癌化疗患者中性粒细胞减少症的临床治疗效果。方法选择南京市胸科医院收治的非小细胞肺癌化疗患者150例,按照随机数字表法分为芪胶升白组和对照组,每组75例,给予对照组患者化疗,给予芪胶升白组患者化疗+芪胶升白胶囊治疗,观察2组患者化疗前后中性粒细胞水平变化,在试验过程中同时采取必要的药学监护。结果芪胶升白组临床治疗总有效率显著优于对照组(81.33 vs 62.67%,P<0.05),芪胶升白组治疗后重度中性粒细胞减少症发生率显著少于对照组(5.33%vs 25.33%,P<0.05);芪胶升白组重度中性粒细胞减少症的持续时间为(1.37±0.56)d,显著短于对照组的(2.14±0.70)d,差异具有统计学意义(P<0.05);芪胶升白组生活质量改善率显著高于对照组(45.33%vs 25.33%,P<0.05)。结论芪胶升白胶囊可提高化疗效果,降低中性粒细胞减少症的发生率,应用安全,不良反应小,值得临床大力推广。

Objective To discuss the clinical curative efficacy of Qijiaoshengbai capsule in improving the non-small cell lung cancer for patients with neutropenia caused by chemotherapy.Methods 150 patients with non-small cell lung cancer chemotherapy admitted to Nanjing Chest hospital were selected and were randomly divided into study group and control group with 75 cases in each group. The patients in the control group were treated with chemotherapy, and the patients in the study group were treated with chemotherapy combined with Qijiaoshengbai Capsule. The changes of neutrophils in the two groups before and after chemotherapy were observed with necessary pharmaceutical care adopted in the process of experiment.Results The total effective rate of clinical treatment in study groupwas significantly better than that of the control group （81.33% vs 62.67%,P〈0.05）. The incidence of posttreatment severe neutropenia in the study group was significantly less than that of the control group （（5.33% vs 25.33%,P〈0.05）. The duration of severe neutropenia in the study group was （1.37±0.56）d, which was significantly shorter than （2.14±0.70）d in the control group and the difference was statistically significant （P〈0.05）. The ratio of life quality improvement of the study group was significantly higher than that of the control group（45.33% vs 25.33%,P〈0.05）.Conclusion Qijiaoshengbai Capsule can improve the efficacy of chemotherapy, reduce the incidence of neutropenia and ease toxic side effect. As a result, it is worthy of clinical promotion.